Smurfit Westrock, a global paper-based packaging provider, has inaugurated a new €40 million clinical and adherence packaging facility at Dublin Airport, marking a significant investment in regulated pharmaceutical packaging and clinical trial support.

The facility, designed to replicate pharmaceutical manufacturing environments, aims to improve patient adherence and provide enhanced data collection for clinical studies. It houses a 170-person team of specialised designers, operators, and support staff. The site also includes an Experience Centre to showcase capabilities to clients and partners.

Tony Smurfit, President and CEO, highlighted that the facility’s design and operations will contribute to the development of the next generation of medicines. The investment underscores Smurfit Westrock’s role in supporting Europe’s clinical trial and pharma packaging requirements.

Strategically positioned to serve European markets, the Dublin facility complements Smurfit Westrock’s international operations, including sites in Kunshan, China, and Mebane, North Carolina, USA. The company employs approximately 100,000 staff across 40 countries, maintaining a global footprint in paper-based and specialty packaging solutions.

Packaging solutions play a critical role in clinical trials, influencing patient adherence, trial accuracy, and data quality. Smurfit Westrock’s expansion reflects rising demand for high-quality packaging in life sciences and the company’s focus on integrating design, operational excellence, and compliance in regulated environments.

The new facility aligns with increasing pharmaceutical R&D investments in Europe, offering advanced packaging capabilities for complex trial requirements. It is expected to accelerate client timelines and enhance product delivery across regulated markets.

Explore the full article for detailed insights on Smurfit Westrock’s investment and its impact on European pharmaceutical packaging.